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ABSTRACT 
Objective: The aim of present work was to develop of pediatric cefuroxime axetil 125 mg dispersible tablets by using ion exchange resin as a taste 
masking agent and quality target product profile was defined based on the properties of the cefuroxime axetil. 
Methods: Initially, cefuroxime axetil and various resin complexes (DRC) were prepared with different conditions and evaluated for taste masking 
and drug loading. Optimized DRC was used to formulate the dispersible tablet. A 32 full factorial design was employed to study the effect of mannitol 
(X1) and microcrystalline cellulose PH-101 (X2) on drug release at 10 min and time taken to 80% drug release. In the present study, the following 
constraints were arbitrarily used for the selection of an optimized batch: Q10>65% and T80%<
Results: Among the various drug resins complex DRC-9 was found with less bitter taste which was containing kyron T-114 and among the all 
factorial batch F
30 min. Multiple linear regression analysis, ANOVA and 
graphical representation of the influence factor by 3D plots were performed by using Sigmaplot 11.0. Checkpoint batch was prepared to validate the 
evolved model.  
7 showed highest drug release at 10 min (Q10) and lowest time taken to 80% drug release (T80) hence batch F7
Conclusion: The results of full factorial design indicate mannitol and MCC PH-101 have a significant effect on drug release. 
 was selected as an 
optimized batch and it’s found to be stable in the stability evaluation. 
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Oral route of drug administration is the most appealing route for 
drug delivery. Among the various dosage forms tablet is one of the 
most preferred dosage forms because of its ease of manufacturing, 
convenience in administration, accurate dosing, and stability 
compared with other forms etc. A number of orally administered 
drugs exhibit natural bitter taste that creates an unpleasant feeling 
in the mouth [1, 2]. Therefore, it is necessary to reduce or mask the 
bitterness for enhancing patient acceptability and improving oral 
palatability of bitter drugs. Cefuroxime axetil has a broad spectrum 
antibacterial agent with a bitter taste, so it is necessary to mask the 
bitter taste for pediatric patients [3, 4]. Different methods have been 
suggested for masking of the bitter taste, which includes coating, 
inclusion complexes, molecular complexes, solid dispersion, 
microencapsulation, multiple emulsions, liposome's, Prodrugs and 
mass extrusion method from that ion exchange resin is one of most 
extensively method to overcome this problem [5, 6].  
The present study was aimed to prepare the drug-resin complex 
(DRC) of cefuroxime axetil and evaluate for taste and drug loading. It 
was compressed into tablets by direct compression method. A 32 full 
factorial design was employed to study the effect of mannitol (X1) 
and MCC PH-101 (X2) on drug release at 10 min (Q10) and time is 
taken to 80 % drug release (T80). In the present study, the following 
constraints were arbitrarily used for the selection of an optimized 
batch: Q10>65 % and T80%
MATERIALS AND METHODS 
<30 min [7, 8]. 
Materials and reagents 
Cefuroxime axetil was received as a generous gift from Lincoln 
pharmaceutical Ltd., Ahmedabad, Gujarat, India. Kyron T 114 and 
kyron T 134 was obtained from Corel pharma ltd., Ahmedabad, 
Gujarat, India. Microcrystalline cellulose PH 101 and mannitol were 
purchased from Astron chemicals, Mumbai, Maharashtra, India. All 
other materials and chemicals used were of either pharmaceutical or 
analytical grade. 
Drug excipients compatibility study 
The physicochemical compatibilities of the drug and excipients were 
tested by differential scanning calorimetric (DSC) analysis. 
Thermograms of cefuroxime axetil, drug-resin complex and drug-
excipients physical mixture were derived from DSC with a thermal 
analysis performed by using an automatic thermal analyzer system 
(DSC 60, Shimadzu, Japan). The analysis was performed at a rate of 
20 °C/min from 50 °C to 300 °C under a nitrogen flow of 25 ml/min 
[9, 10]. 
Development and evaluation of drug-resin complex (DRC) 
In the batch process, the activated resin was placed in a beaker 
containing deionised water and allows swelling for 30 min. 
accurately weighed cefuroxime axetil was added and stirred for 
different periods of time at various pH as shown in table 3. The 
mixtures were filtered and the residue was washed with deionised 
water to remove the loosely adsorbed drug from the surface. DRC 
was allowed to dry at room temperature and was stored in a tightly 
closed container. DRC was evaluated for taste and drug loading. 
Taste of drug-resin complexes was subjected to gustatory sensory 
evaluation test performed by a panel of ten volunteers. The 
volunteers were selected randomly and instructed to rate the 
samples as per the taste evaluation scale. For drug loading analysis 
50 mg of DRC was added in 0.1 N HCL and kept in a sonicator for 30 
min. The samples were withdrawn and taking absorbance at 277 nm 
[11, 12]. 
Preliminary trail of cefuroxime axetil 125 mg dispersible 
tablets  
Cefuroxime axetil 125 mg dispersible tablets was prepared according 
to the formula given in table 1. All the ingredients were passed 
through 60# sieve separately and mixed in geometrical order. First 
MCC, mannitol, SSG were mixed together then add the DRC and mixed 
for 10 min. Finally, sodium saccharin or aspartame, sodium stearyl 
fumarate or magnesium stearate and talc were mixed for 10 min. 
Compression was carried out using 11 mm punch set. All the batches 
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were stored properly and evaluation was carried out [13, 14]. 
Evaluation of cefuroxime axetil 125 mg dispersible tablets  
Thickness, hardness, weight variation, % friability and 
disintegration test of the formulations were measured as described 
by Yadav K et al., Khar RK et al., Madgulkar AR et al., and Lakade SH 
et al., respectively [15-18]. 
Wetting time: It can be measured by using five circular tissue papers of 
10 cm in diameter, which are placed in a petridish of 10 cm diameter. 
10 ml of eosin solution is added to the petridish. A tablet is carefully 
placed on the surface of the tissue paper. The time required for water 
to reach the upper surface of the tablet is noted as the wetting time.  
The fineness of dispersion: It is an assessment of the grittiness 
which arises due to the disintegration of the tablet into coarse 
particles. The test was performed by placing two tablets in 100 ml 
water and stirring it gently, till the tablets get completely 
disintegrated. The formulation was considered to form a smooth 
dispersion if the complete dispersion passes through a sieve screen 
with a nominal mesh aperture of 710 μm without leaving any 
residue on the mesh. 
In vitro dissolution study: Drug release studies were carried out 
using by USP II dissolution test apparatus at 37±0.5 °C and 50 rpm. 
In this study, 0.1 N HCl (pH 1.2) was used as a dissolution medium. 
Aliquots of 5 ml were withdrawn at predetermined time intervals 
and an equal amount of fresh dissolution medium was added. The 
solution was suitably diluted and assayed at 277 nm using a UV-Vis 
double-beam spectrophotometer.  
Taste analysis: All the batches of tablets were subjected to the 
gustatory sensory evaluation test performed by a panel of ten 
volunteers. The volunteers selected randomly and instructed to rate 
the samples as per the taste evaluation scale [19, 21]. 
 
Table 1: Preliminary trail formulation of cefuroxime axetil 125 mg dispersible tablets 
S. No. Ingredients X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 X11 X12 X13 X14 
1 DRC* 543 543 543 543 543 543 543 543 543 543 543 543 543 543 
2 Crosspovidone 20 25 - - - - - - - - - - - - 
3 Croscarmellose Sodium - - 20 25 - - 30 - 30 - - - - - 
4 Sodium Starch Glycolate - - - - 20 25 - 30 - 30 40 45 30 30 
5 Aspartame 20 20 20 20 20 20 - - - - - - - - 
6 Sodium Saccharin - - - - - - 20 20 20 20 20 20 20 20 
7 MCC PH-101 56 51 56 51 56 51 46 46 - - - - 15 31 
8 Mannitol - - - - - - - - 46 46 46 46 31 15 
9 Talc 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
10 Magnesium Stearate 7 7 7 7 7 7 7 7 - - -   - - 
11 Sodium Stearyl Fumarate - - - - - - - - 7 7 7 7 7 7 
12 Flavour 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
Total 656 656 656 656 656 656 656 656 656 656 666 671 660 660 
 *Drug resin complex (DRC) contain 125 mg cefuroxime axetil and kyron T-114 
 
Optimization of excipients amount by using 32 full factorial design 
A 32full factorial design was used in the present study. Formulation of 
factorial batches was shown in table 2. On the basis of preliminary 
results, the amount of mannitol (X1) and the amount of MCC PH-101 
(X2) were chosen as independent variables in 32 full factorial design, 
while % drug release at 10 min (Q10%) and time required for 80% drug 
release (t80). were taken as dependent variables. Multiple linear 
regression analysis, ANOVA and graphical representation of the 
influence of factor by contour plots were performed using Sigmaplot 
11.0. The experimental runs and measured responses of 32
Stability study 
 full 
factorial design batches of cefuroxime axetil dispersible tablets were 
depleted in table 6. [22-24]. 
Optimized batch was packed in aluminum foil and was placed for 
stability study at 40˚C/75% RH for 3 mo. Sample was evaluated after 
3 mo for physical parameters and In vitro dissolution. The 
dissolution profile of the product was compared using the similarity 












where the log is logarithm to the base 10, n is the number of 
time points, ∑ is summation over all time points, Rt is the mean 
dissolution value of the reference profile at time t and Tt is the 
mean dissolution value of the test profile at the same time point. 
The USFDA draft guidance document contains more information 
on the similarity factor (f2). The value of the similarity factor (f2) 
between 50 and 100 suggests that the two dissolution profiles 
are similar [25-27]. 
 
Table 2: Formulation of factorial batches of cefuroxime axetil 125 mg dispersible tablets 
S. No. Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 DRC 543 543 543 543 543 543 543 543 543 
2 SSG 30 30 30 30 30 30 30 30 30 
3 Mannitol 15 15 15 25 25 25 35 35 35 
4 MCC (PH 101) 15 25 35 15 25 35 15 25 35 
5 Sodium Saccharin 20 20 20 20 20 20 20 20 20 
6 Talc 8 8 8 8 8 8 8 8 8 
7 Sodium Stearyl Fumarate 7 7 7 7 7 7 7 7 7 
8 Flavour 5 5 5 5 5 5 5 5 5 
 TOTAL 643 653 663 653 663 673 663 673 683 
 *Drug resin complex (DRC) contain 125 mg cefuroxime axetil and kyron T-114 
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RESULTS AND DISCUSSION 
Drug-excipient compatibility study 
Compatibility studies of pure drug with ion-exchange resin and 
other excipients were carried out prior to the preparation of taste 
masked dispersible tablet. Fig. 1 and fig. 2 shows DSC thermograms 
of cefuroxime axetil and kyron T-114, respectively. Fig. 3 and fig. 4 
shows DSC thermograms of drug-resin complex and Drug-excipients 
physical mixture, respectively. The DSC analysis of the drug alone 
elicited a peak at 255.22 °C and complex of cefuroxime axetil with 
kyron T-114 shows peak of drug at 256.78 °C. Elicited peak of the 
physical mixture of DRC and other excipients was found to be at 
254.16 °C. Thus, it was thought to indicate that there was no 
evidence of interactions between cefuroxime axetil, kyron T-114 and 
the used excipients. So, it can conclude that drug and other 
excipients are compatible which each other [28, 29]. 
 
 
Fig. 1: DSC spectrum of cefuroxime axetil 
 
Fig. 2: DSC spectrum of kyron T-114 
 
Fig. 3: DSC spectrum of drug-resin complex 
 
Fig. 4: DSC spectrum of physical mixture of drug-resin and excipients 
 
Evaluation of drug-resin complex (DRC) 
Trial batches of cefuroxime axetil-resin complex were prepared 
using different drug-resin ratio, different resins, pH and 
temperature. Taste and % of drug loading of all the formulation 
were shown in table 3. Indion-214 showed a higher percentage of 
drug loading but it cannot mask the bitter taste. The same condition 
was found with kyron T-134. Among the all batches DRC-9 showed 
less bitter taste and 92.70% of drug loading may be due to drug got 
ionised and cross-linked with kyron T-114 at pH 9. So, DRC-9 was 
use for further studies to prepare cefuroxime axetil dispersible 
tablet [30]. 
 
Table 3: Development and evaluation of drug-resin complex (DRC) 
Formulation Resin Ratio pH Time(hr) Temp Taste % Drug loading 
DRC-1 Indion-214 1:1 7 2 30±0.5 °C ++++ 59.21±1.3% 
DRC-2 Indion 214 1:2 7 2 30±0.5 °C ++++ 71.92±1.6% 
DRC-3 Indion 214 1:3 9 3 30±0.5 °C ++++ 82.24±0.8% 
DRC-4 Indion 214 1:3 9 3 35±0.5 °C +++ 87.73±0.4% 
DRC-5 Kyron T-114 1:1 7 2 30±0.5 °C ++++ 68.23±0.7% 
DRC-6 Kyron T-114 1:2 7 2 30±0.5 °C ++++ 77.49±1.4% 
DRC-7 Kyron T-114 1:3 7 3 30±0.5 °C +++ 84.27±1.3% 
DRC-8 Kyron T-114 1:3 9 3 30±0.5 °C ++ 88.39±0.7% 
DRC-9 Kyron T-114 1:3 9 3 35±0.5 °C + 92.70±0.3% 
DRC-11 Dosion P551 1:2 7 3 30±0.5 °C ++++ 62.80±1.5% 
DRC-10 Kyron T 134 1:1 7 3 30±0.5 °C ++++ 62.23±1.1% 
DRC-12 Kyron T 134 1:2 7 3 30±0.5 °C +++ 76.21±1.3% 
DRC-13 Kyron T 134 1:3 7 3 35±0.5 °C +++ 84.61±0.6% 
DRC-14 Kyron T 134 1:3 9 3 3±0.55 °C +++ 89.62±1.2% 
++++= Very bitter,+++= Bitter,++= Less bitter,+= Very less bitter 
 (n=6) 
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Preliminary trail batch evaluation of cefuroxime axetil 125 mg 
dispersible tablets  
Table 4 shows the results of pre-compression, post-compression and 
In vitro drug release at 45 min of preliminary trail batches of 
dispersible tablets. The hardness and friability of all the formulation 
was found to be in a range of 1.9 to 3.9 kg/cm3
 
and 0.30 to 0.70 
respectively. Trail batches of dispersible tablets indicate that 
hardness dependent on MCC and mannitol concentration. Batch X5 
and X6 shows less disintegration time compared to batch X1, X2, X3 
and X4. Croscarmellose Sodium was increased in batch X7 but it will 
not impact on disintegration time. So, sodium starch glycolate was 
used as super disintegrants for further Preliminary trial batch. 
Sodium starch glycolate further increase in batch X11 and X12 but it 
decreases hardness of tablet and less impact on disintegration time. 
In Batch X13 and X14; MCC and mannitol was taken as filler for 
tablet. X13, X14 gave 94.61% and 89.65% drug release in 45 min, 
respectively. The results of preliminary study revealed that MCC or 
mannitol alone was not sufficient to achieve the desired release 
profile. Hence, further trials were carried out using combination 
MCC and mannitol in order to understand their effect and to 
optimize concentration of both for desired release profile [31, 32]. 











































































































































































































































































































































































































































32 full factorial design model evaluation  
A statistical model incorporating interactive and polynomial terms 
was used to evaluate the responses:  
Y=b0+b1X1+b2X2+b11X12+b22X22
where, Y is the dependent variable, bo is the arithmetic mean 
response of the 9 runs and any bi is the estimated coefficients for the 
related factor Xi. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high value. The 
polynomial terms (X1
+b12X1X2 
2 and X22) are included to investigate 
nonlinearity. The interaction term “X1X2” shows how the response 
changes when the two factors change simultaneously. Evaluation 
data of pre-compression and post-compression parameters of 
factorial batches and In vitro % drug release were presented in table 
5 and table 6. Table 7 describes the effect of independent variables 
on dependent variables by 32 full factorial designs. The fitted 
equations (full model) relating the responses that is % drug release 
at 10 min (Q10%) and time required for 80% drug release (min) (T80) 
to the transformed factor were shown in table 8. The polynomial 
equation can be used to draw conclusion after considering the 
magnitude of coefficient and the mathematical sign it carries (i.e. 
positive or negative). The results of ANOVA suggested that F values 
calculated for Q10% and t80% are 59.668 and 92.625, respectively 
(table 8). Tabulated F value was found to be 9.013 at α = 0.05. 
Calculated F values are greater than tabulated for all dependent 
variables therefore factors selected have shown significant effects. 
From the results of multiple regression analysis, it was found that 
both factors had statistically significant influence on all dependent 
variables as p<0.05 [33, 34]. 
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Table 5: Factorial batch evaluation of cefuroxime axetil 125 mg dispersible tablets 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 




















































































































































































11 Wetting time 18±1 17±2 14±1 13±1 11±2 10±2 8±1 10±1 12±2 
12 Disintegration time 14±1 15±2 17±1 13±1 15±2 16±2 12±1 13±2 14±1 
13 Fineness of dispersion Pass Pass Pass Pass Pass Pass Pass Pass Pass 
 (n=6) 
 
Table 6: In vitro dissolution of factorial batches 
Time (min) F1 F2 F3 F4 F5 F6 F7 F8 F9 

































































































































Table 7: Runs and measured responses of 32
Batch 




Inlet air temperature 
(X2) 
% Drug release at 10 min (Q10%) 
Y1 
Time required for 80% drug release (min) (T80) 
Y2 
F1 -1 -1 60.18±1.09 31±2 
F2 0 -1 59.53±0.49 32±1 
F3 1 -1 58.36±0.85 33±1 
F4 -1 0 68.83±0.77 26±2 
F5 0 0 67.47±0.69 26±1 
F6 1 0 64.61±1.07 27±2 
F7 -1 1 69.14±1.09 25±1 
F8 0 1 67.44±0.59 26±1 
F9 1 1 66.15±0.55 27±2 
Factors and the levels in the design 
Independent variables Low (-1) Medium (0) High (1) 
Mannitol (X1) 15 25 35 
MCC PH-101 (X2) 15 25 35 
(n=6) 
 
Full and reduced model for % drug release at 10 min 
Q10% = 67.153-(1.505 X1)+(4.111 X2)-(0.294X12)-(0.270 X22
From the 3D plot (fig. 5) and the regression coefficient values of 
factors, it was concluded that when MCC PH-101 concentration was 
increase that time drug release also increase due to its hydrophilic )-(3.501 X1X2) 
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nature. For drug release at 10 min, the significance levels of the 
coefficients b11 and b22 were found to be P = 0.454, and 0.617 
repectively, so they were omitted from the full model to generate a 
reduced model. The coefficients b0, b1, b2 and b12 significant at 
P<0.05; hence they were retained in the reduced model. [35, 36] The 
reduced model for drug release at 10 min:  
Q10% = 67.153-(1.505 X1)+(4.111 X2)-(3.501 X1X2) 
Full and reduced model for time required for 80% drug release 
T80 = 26.611+(0.833 X1)-(2.917 X2)-(-0.000 X12)-(0.167 X22
From the 3D plot graph (fig. 6) and the regression coefficient values 
of factors, it was concluded that when mannitol concentration was 
increase that time drug release decrease may be due to its very low 
hydrophilic nature. For time required for 80% drug release, the 
significance levels of the coefficients b11 and b22 were found to be P = 
1.00, and 0.584 repectively, so they were omitted from the full 
model to generate a reduced model. The coefficients b0, b1, b2 and b12 
significant at P<0.05; hence they were retained in the reduced 
model. [37, 38] The reduced model for Drug release time required 
for 80% drug release:  
)+(2.583 
X1X2) T80 = 26.611+(0.833 X1)-(2.917 X2)+(2.583 X1X2) 
 
Table 8: Results of the ANOVA for dependent variables 
Source of variation DF SS MS F value P value 
Q10 Dependent variable 
Regression 5 139.975 27.995  
59.668 
 
0.003 Residual 3 1.408 0.469 
Total 8 141.382 17.673 
t80 Dependent variable 
Regression 5 68.611 13.722 92.625 0.002 
Residual 3 0.444 0.148 
Total 8 69.056 8.632 
 
Table 9: Summary of regression output of factors for measured responses 
Responses Model Coefficient of regression parameters 
b0 b1 b2 b11 b22 b12 R2 
 Q10% Full 67.153 -1.505 4.111 0.294 -0.270 -3.501 0.990 
Reduced 67.153 -1.505 4.111 - - -3.501 - 
T80 Full 26.611 0.833 -2.917 -0.000 -0.167 2.583 0.994 

















































Fig. 5: 3D ssplot showing the effect of conc. of mannitol (X1) and 













































 Fig. 6: 3D plot showing the effect of conc. of mannitol (X1) and MCC 
PH-101 (X2) on time required for 80% drug release 
 
Formulation of check point batch 
To validate the evolved mathematical models, a check point batches 
CP1 was prepared and evaluated. The observed and predicted values 
for batch CP1 were shown in table 10. Good correlation was found 
between observed and predicted values shown in table 11. Hence, it 
was concluded that the evolved models may be used for theoretical 
prediction of responses within the factor space [22]. 
Selection of optimized batch in factorial design study 
In the present study, the following constraints were arbitrarily used for 
the selection of an optimized batch: Q10>65 % and T80%<30 min. Batches 
F4, F5, F7, F8 and F9 met the selection criteria. Batch F7 showed higest % 
drug release at 10 min (69.149) and lowest time required for 80% drug 
release (25 min), Hence, Batch F7 was selected as an optimized batch. 
The optimized formulation was subjected to accelerated stability study. 
 
Table 10: Formulation and evaluation of check point batches 
Batch code Variable level 
Coded value Actual value 
X1 X2 X1(mg) X2(ml) 
CP1 -0.5 -0.5 20 20 
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Table 11: Of check point batches and comparison with predicted value 
Parameter Actual value Predicted value 
% drug release at 10 min (Q10%) 63.54±1.35 64.99 
Time required for 80% drug release (T80) 27±1 28.63 
(n=6) 
 
Table 12: Comparison of Evaluation parameters of optimized batch F7 under stability study 
S. No. Parameters Initial After 3 mo 
1 Hardness (kg/cm2 2.74±0.51 ) 2.55±0.33 
2 Average weight (mg) 662.65±4.64 660.15±2.11 
3 Disintegration time (min) 12±1 13±2 
(n=6) 
 
Short term stability study 
Batch F7 was kept for stability study. The in vitro release profile at 
initial and after 3 mo was compared using similarity factor, f2, value 
which was found to be 86.50. There is no significant difference in 
similarity factor. Evaluation parameter of stability parameter was 
shown in table 12. 
CONCLUSION 
The objective of the present investigation was to formulate, evaluate 
and optimize the cefuroxime axetil 125 mg dispersible tablets to 
achieve quick disintegration and fast release of the drug for paediatric 
patients. Kyron T-114 was used as teste masking agent that showed 
highest % of drug loading and test masking. These formulations were 
evaluated for the parameters like drug excipient compatibility study, 
thickness, hardness, weight variation, % friability, disintegration test, 
in vitro drug release and accelerated stability studies. On the basis of 
preliminary results, the amount of mannitol (X1) and the amount of 
MCC PH-101 (X2) were chosen as independent variables in 32
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